Clinical value of fluoroquinolone in the treatment of TB and MDR-TB

Tuberculosis is a major health problem in many developing countries. The disease is caused by Mycobacterium tuberculosis bacilli, for the treatment antibiotics such as isoniazid, rifampin, pyrazinamide and ethambutol are used, Due to the reduced activity of these antibiotics and increase the resistance and MDR strains around the world, need to consider antibiotics second phase of TB treatment and alternative therapies felt. Among the second phase of treatment drugs, fluoroquinolone are the most important drugs as the second phase of TB treatment because of high pharmoacokenetics and pharmaco dynamic properties , Broad activity against Mycobacterium tuberculosis and less side effects and toxicity. As currently only fluoroquinolone is approved by the World Health Organization to be used in the treatment of sensitive TB and proved that their use shortens the duration of treatment and improve results.
In the present study, 170 Article about fluoroquinolone in the treatment of pulmonary tuberculosis and MDR-TB have been reviewed.
According to the articles , fluoroquinolone are the latest and most powerful drug classes used in the second phase of TB treatment and In addition to being effective in the treatment of MDR-TB, affordable alternative to antibiotics in the first phase standard diet. Among the members of this groupof antibiotics ,Moxifloxacin and levofloxacin of which have the greatest activity and Have higher activity than ofloxacinBut there ofloxacin higher safety
fluoroquinolone, as appropriate antibiotic for the treatment of MDR-TB as well as a better alternative to antibiotics in the first line.